Table 4.
Study Characteristics: Author/Yr N Design-Quality Score | Population | Treatment | ||
---|---|---|---|---|
Treatment | Dosage/Frequency | Time post Injury | ||
Kolessar et al. 1996 N=17 Case series-D&B=15 |
BI | Excision/Indomethacin/Etidronate | Indomethacin (75 mg/day) + Etidronate (20 mg/kg/day) | Mean of 30 months |
Fuller et al. 2005 N=17 Case series-D&B=14 |
BI | Excision/Etidronate | 20 mg/kg body weight for 2 months | Not stated |
Lazarus et al. 1999 N=24 Pre-Post-D&B=13 |
BI | Excision/Indomethacin | Indomethacin 25–50mg | Average of 35.4 months |
Ippolito et al. 1999a N=12 Pre-Post-D&B=12 |
BI | Excision | N/A | Not stated |
Moore 1993 N=17 Case series-D&B=9 |
BI | Excision/Etidronate | 10mg/kg body weight per day for 3 months | Not stated |
Schuetz et al. 2005 N=5 Case studies-D&B=9 |
SCI | Excision/Pamidronate | 120 mg for 12 hrs post surgery and then increase over 6–14 days. | Not stated |
Subbarao et al. 1987 N=5 Case series-D&B=8 |
SCI | Excision/Etidronate | 20 mg/kg body weight preoperatively for 10–14 days 10 mg/kg body weight post-operatively for at least 3 months |
Not stated |
Kolessar et al. 1996 N=17 Case series-D&B=15 |
BI | Excision/Indomethacin/Etidronate | Indomethacin (75 mg/day) + Etidronate (20 mg/kg/day) | Mean of 30 months |
Charnley et al. 1996 N=5 Case series-D&B=9 |
BI | Excision/Indomethacin | Not stated | Over 18 months |
De Palma et al. 2002 N=10 Case series-D&B=8 |
BI | Excision/Indomethacin/active motion therapy | 25 mg 3 times a day for 6 weeks | 18–20 months |